title: Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study.
abstract: The purpose of this study was to investigate whether whole-liver radiotherapy plus a tumor-boost dose with concurrent chemotherapy is beneficial for colorectal cancer patients with massive and multiple liver metastases. From January 2007 to December 2012, 19 patients who exhibited massive (with a longest diameter > 5 cm) and invasive liver metastases and multiple metastases were treated with radiotherapy and concurrent chemotherapy. The total radiation dose was 53.4 Gy (range 38.8 Gy-66.3 Gy). All of the patients received a continuous intravenous dose of 5 fluorouracil (5-FU) 225 mg/m2 concurrently with radiation. The median survival time was 19 months. The 1- and 2- year overall survival rates were 78.3% and 14.3%, respectively. Of all of the patients who presented with abdominal pain, 100% experienced a decrease in pain. Decreases in the rates of ascites and jaundice were confirmed by ultrasound and bilirubin levels. No cases of Grade 4 or 5 acute or late toxicity were recorded. There were only two cases of Grade 3 toxicity (elevated bilirubin). These data provide evidence that whole-liver radiotherapy plus a tumor-boost dose with concurrent chemotherapy is beneficial for colorectal cancer patients with massive and multiple liver metastases.
authors.affiliation: Department of Radiotherapy, the Cancer Hospital of Harbin Medical University, Harbin, China E-mail : 247625923@qq.com.
authors.forename: Hang
authors.initials: H
authors.lastname: Yin
authors.forename: Kai
authors.initials: K
authors.lastname: Lu
authors.forename: Wen-Bo
authors.initials: WB
authors.lastname: Qiao
authors.forename: Hai-Yang
authors.initials: HY
authors.lastname: Zhang
authors.forename: Di
authors.initials: D
authors.lastname: Sun
authors.forename: Qing-Shan
authors.initials: QS
authors.lastname: You
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001201:Ascites / Q000000981:diagnostic imaging / Q000517:prevention & control; D001663:Bilirubin / Q000097:blood; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007565:Jaundice / Q000000981:diagnostic imaging / Q000517:prevention & control; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000532:radiotherapy*; D010166:Palliative Care; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D014463:Ultrasonography
chemical_list: D000964:Antimetabolites, Antineoplastic; D001663:Bilirubin; D005472:Fluorouracil